Antithrombin is protective against myocardial ischemia and reperfusion injury

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1020-1028

  Wang, J ^a,a   Wang, Y ^a   Gao, J ^a   Tong, C ^a   Manithody, C ^b   Li, J ^a   Rezaie, A R ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; Heparin; Inflammation; Ischemia; Signal transduction

Indexed keywords

ANTITHROMBIN; FONDAPARINUX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROSTACYCLIN; PROTEOHEPARAN SULFATE; STRESS ACTIVATED PROTEIN KINASE; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEUKOCYTE; MOUSE; MUTANT; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; WILD TYPE;

ANTITHROMBIN; HEPARIN; INFLAMMATION; ISCHEMIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTITHROMBINS; CARDIOTONIC AGENTS; HEPARIN; INFLAMMATION; INTERLEUKIN-6; ISCHEMIA; LEUKOCYTES; MALE; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; MUTATION; MYOCARDIAL ISCHEMIA; NF-KAPPA B; POLYSACCHARIDES; REPERFUSION INJURY; SIGNAL TRANSDUCTION; THROMBIN; TROPONIN I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883783200     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12243     Document Type: Article

References (34)

1. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-60.
2. Jin L, Abrahams J, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci (USA) 1997; 94: 14683-8.
3. Gettins PGW. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-803.
4. Lawrence DA. The serpin-proteinase complex revealed. Nature Struct Biol 1997; 4: 339-41.
5. Weitz JI, Hirsh J. Antithrombins: their potential as antithrombotic agents. Annu Rev Med 1992; 43: 9-16.
6. Huntington JA, McCoy A, Belzar KJ, Pei XY, Gettins PGW, Carrell RW. The conformational activation of antithrombin. J Biol Chem 2000; 275: 15377-83.
7. Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from the vascular tissue. Biochemistry 1984; 23: 1730-7.
8. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-7.
9. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8.
10. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-70.
11. Rein CM, Desai UR, Church FC. Serpin-glycosaminoglycan interactions. Methods Enzymol 2011; 501: 105-37.
12. Zhang W, Chuang YJ, Swanson R, Li J, Seo K, Leung L, Lau LF, Olson ST. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-91.
13. Zhang W, Swanson R, Izaguirre G, Xiong Y, Lau LF, Olson ST. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005; 106: 1621-8.
14. Mizutani A, Okajima K, Uchiba M, Isobe H, Harada N, Mizutani S, Noguchi T. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-6.
15. Dunzendorfer S, Kaneider N, Rabensteiner A, Meiehofer C, Reinisch C, Romisch J, Wiedermann CJ. Cell-surface heparin sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-85.
16. Minnema MC, Chang ACK, Jansen PM, Lubbers YTP, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-23.
17. Zhang W, Chuang YJ, Jin T, Swanson R, Xiong Y, Leung L, Olson ST. Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006; 66: 5047-55.
18. Shworak NW, Kobayashi T, De Agostini A, Smits NC. Anticoagulant heparan sulfate: to not clot-or not? Prog Mol Biol Transl Sci 2010; 93: 153-78.
19. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93: 157-64.
20. Wiedermann CJ, Hofmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke H-O, Warren BL, Opal SM, forthe KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety. Crit Care Med 2006; 34: 285-92.
21. Rezaie AR, Yang L. Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin. Biochem Biophys Acta 2001; 1528: 167-76.
22. Rezaie AR. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Thromb Res 2006; 119: 481-8.
23. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008; 451: 578-82.
24. Wang J, Yang L, Rezaie AR, Li J. Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. J Thromb Haemost 2011; 9: 1308-17.
25. Costa R, Morrison A, Wang J, Manithody C, Li J, Rezaie AR. Activated protein C modulates cardiac metabolism and augments autophagy in the ischemic heart. J Thromb Haemost 2012; 10: 1736-44.
26. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97: 2308-13.
27. Yang L, Manithody C, Qureshi SH, Rezaie AR. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin. Thromb Haemost 2010; 103: 277-83.
28. Bae JS, Rezaie AR. Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin. J Thromb Haemost 2009; 7: 803-10.
29. Kawano S, Kubota T, Monden Y, Tsutsumi T, Inoue T, Kawamura N, Tsutsui H, Sunagawa K. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 291: H1337-44.
30. Brown MA, Jones WK. NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 2004; 9: 1201-17.
31. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases-regulating the immune response. Nat Rev Immunol 2007; 7: 202-12.
32. McDonough JL, van Eyk JE. Developing the next generation of cardiac markers: disease-induced modifications of troponin I. Prog Cardiovasc Dis 2004; 47: 207-16.
33. Howie-Esquivel J, White M. Biomarkers in acute cardiovascular disease. J Cardiovasc Nurs 2008; 23: 124-31.
34. Hoffmann JN, Mühlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004; 32: 1851-9.